메뉴 건너뛰기




Volumn 101, Issue 2, 2012, Pages 115-121

New biomarkers in prostate cancer;Neue biomarker für prostatakarzinom

Author keywords

Biomarkers; Multiplexing assay; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN;

EID: 84856015443     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/1661-8157/a000819     Document Type: Short Survey
Times cited : (1)

References (55)
  • 3
    • 0035667653 scopus 로고    scopus 로고
    • Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium
    • DOI 10.1016/S0090-4295(01)01441-8, PII S0090429501014418
    • Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843-8. (Pubitemid 34017254)
    • (2001) Urology , vol.58 , Issue.6 , pp. 843-848
    • Partin, A.W.1    Mangold, L.A.2    Lamm, D.M.3    Walsh, P.C.4    Epstein, J.I.5    Pearson, J.D.6
  • 4
    • 0036783942 scopus 로고    scopus 로고
    • A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria
    • Gretzer MB, Trock BJ, Han M, Walsh PC. A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria. J Urol. 2002;168:1419-22. (Pubitemid 35034137)
    • (2002) Journal of Urology , vol.168 , Issue.4 I , pp. 1419-1422
    • Gretzer, M.B.1    Trock, B.J.2    Han, M.3    Walsh, P.C.4
  • 6
    • 35748967549 scopus 로고    scopus 로고
    • Prospective Validation of Active Surveillance in Prostate Cancer: The PRIAS Study
    • DOI 10.1016/j.eururo.2007.05.011, PII S0302283807007130
    • van den Bergh RC, Roemeling S, Roobol MJ, Roobol W, Schroder FH, Bangma CH. Prospective validation of active surveillance in prostate cancer: the PRIAS study. Eur Urol. 2007;52:1560-3. (Pubitemid 350052404)
    • (2007) European Urology , vol.52 , Issue.6 , pp. 1560-1563
    • Van Den, B.R.C.N.1    Roemeling, S.2    Roobol, M.J.3    Roobol, W.4    Schroder, F.H.5    Bangma, C.H.6
  • 7
    • 77958547574 scopus 로고    scopus 로고
    • PSA kinetics: No substitute for annual biopsy in prostate cancer surveillance?
    • Schmidt C. PSA kinetics: no substitute for annual biopsy in prostate cancer surveillance? J Natl Cancer Inst. 2010;102:1533-5.
    • (2010) J Natl Cancer Inst , vol.102 , pp. 1533-1535
    • Schmidt, C.1
  • 8
    • 65049084253 scopus 로고    scopus 로고
    • Insignificant prostate cancer and active surveillance: From definition to clinical implications
    • Bastian PJ, Carter BH, Bjartell A, Seitz M, Stanislaus P, Montorsi F, et al. Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol. 2009;55:1321-30.
    • (2009) Eur Urol , vol.55 , pp. 1321-1330
    • Bastian, P.J.1    Carter, B.H.2    Bjartell, A.3    Seitz, M.4    Stanislaus, P.5    Montorsi, F.6
  • 9
    • 0038509980 scopus 로고    scopus 로고
    • Quality of life and economic considerations in the management of prostate cancer
    • DOI 10.2165/00019053-200321080-00001
    • Turini M, Redaelli A, Gramegna P, Radice D. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics. 2003;21:527-41. (Pubitemid 36688098)
    • (2003) PharmacoEconomics , vol.21 , Issue.8 , pp. 527-541
    • Turini, M.1    Redaelli, A.2    Gramegna, P.3    Radice, D.4
  • 11
    • 77955279420 scopus 로고    scopus 로고
    • Mortality results from the Goteborg randomised population-based prostate-cancer screening trial
    • Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11:725-32.
    • (2010) Lancet Oncol , vol.11 , pp. 725-732
    • Hugosson, J.1    Carlsson, S.2    Aus, G.3    Bergdahl, S.4    Khatami, A.5    Lodding, P.6
  • 12
    • 3342964033 scopus 로고    scopus 로고
    • Biomarker discovery and validation: Technologies and integrative approaches
    • DOI 10.1016/j.tibtech.2004.06.005, PII S0167779904001702
    • Ilyin SE, Belkowski SM, Plata-Salaman CR. Biomarker discovery and validation: technologies and integrative approaches. Trends Biotechnol. 2004;22:411-6. (Pubitemid 38993225)
    • (2004) Trends in Biotechnology , vol.22 , Issue.8 , pp. 411-416
    • Ilyin, S.E.1    Belkowski, S.M.2    Plata-Salaman, C.R.3
  • 14
    • 79957456529 scopus 로고    scopus 로고
    • Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers
    • Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol. 2011;50:76-84.
    • (2011) Acta Oncol , vol.50 , pp. 76-84
    • Bjartell, A.1    Montironi, R.2    Berney, D.M.3    Egevad, L.4
  • 16
    • 79952254227 scopus 로고    scopus 로고
    • KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy
    • Mortezavi A, Hermanns T, Seifert HH, Baumgartner MK, Provenzano M, Sulser T, et al. KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res. 2011;17:1111-21.
    • (2011) Clin Cancer Res , vol.17 , pp. 1111-1121
    • Mortezavi, A.1    Hermanns, T.2    Seifert, H.H.3    Baumgartner, M.K.4    Provenzano, M.5    Sulser, T.6
  • 17
    • 79959269553 scopus 로고    scopus 로고
    • Circulating tumor cells as biomarkers in prostate cancer
    • Danila DC, Fleisher M, Scher HI. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res. 2011;17:3903-12.
    • (2011) Clin Cancer Res , vol.17 , pp. 3903-3912
    • Danila, D.C.1    Fleisher, M.2    Scher, H.I.3
  • 19
    • 0242691892 scopus 로고    scopus 로고
    • PCA3), a highly prostate cancer-specific gene
    • DOI 10.1016/S0090-4295(03)00759-3
    • Schalken JA, Hessels D, Verhaegh G. New targets for therapy in prostate cancer: differential display code 3 (DD3(PCA3)), a highly prostate cancer-specific gene. Urology. 2003;62:34-43. (Pubitemid 37371888)
    • (2003) Urology , vol.62 , Issue.5 SUPPL. 1 , pp. 34-43
    • Schalken, J.A.1    Hessels, D.2    Verhaegh, G.3
  • 21
    • 78049478702 scopus 로고    scopus 로고
    • Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: Reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (>/= 100)
    • Roobol MJ, Schroder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in Prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (>/= 100). Eur Urol. 2010;58:893-9.
    • (2010) Eur Urol , vol.58 , pp. 893-899
    • Roobol, M.J.1    Schroder, F.H.2    Van Leenders, G.L.3    Hessels, D.4    Van Den Bergh, R.C.5    Wolters, T.6
  • 22
    • 3142540904 scopus 로고    scopus 로고
    • PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer
    • DOI 10.1016/j.eururo.2004.06.004, PII S0302283804002829
    • Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine - a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182-6. (Pubitemid 38902733)
    • (2004) European Urology , vol.46 , Issue.2 , pp. 182-186
    • Tinzl, M.1    Marberger, M.2    Horvath, S.3    Chypre, C.4
  • 24
    • 35348955894 scopus 로고    scopus 로고
    • Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization
    • DOI 10.1038/modpathol.3800963, PII 3800963
    • Popa I, Fradet Y, Beaudry G, Hovington H, Tetu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol. 2007;20:1121-7. (Pubitemid 47609070)
    • (2007) Modern Pathology , vol.20 , Issue.11 , pp. 1121-1127
    • Popa, I.1    Fradet, Y.2    Beaudry, G.3    Hovington, H.4    Beaudry, G.5    Tetu, B.6
  • 25
    • 72849117496 scopus 로고    scopus 로고
    • Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer
    • Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70:10-6.
    • (2010) Prostate , vol.70 , pp. 10-16
    • Hessels, D.1    Van Gils, M.P.2    Van Hooij, O.3    Jannink, S.A.4    Witjes, J.A.5    Verhaegh, G.W.6
  • 26
    • 41749088455 scopus 로고    scopus 로고
    • PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance
    • Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804-9.
    • (2008) J Urol , vol.179 , pp. 1804-1809
    • Nakanishi, H.1    Groskopf, J.2    Fritsche, H.A.3    Bhadkamkar, V.4    Blase, A.5    Kumar, S.V.6
  • 27
    • 53449088140 scopus 로고    scopus 로고
    • PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume
    • Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975-8.
    • (2008) J Urol , vol.180 , pp. 1975-1978
    • Whitman, E.J.1    Groskopf, J.2    Ali, A.3    Chen, Y.4    Blase, A.5    Furusato, B.6
  • 30
    • 0037448612 scopus 로고    scopus 로고
    • Molecular biology of the Ets family of transcription factors
    • DOI 10.1016/S0378-1119(02)01156-3
    • Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. Gene. 2003;303:11-34. (Pubitemid 36151767)
    • (2003) Gene , vol.303 , Issue.1-2 , pp. 11-34
    • Oikawa, T.1    Yamada, T.2
  • 31
    • 0028307384 scopus 로고
    • A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG
    • DOI 10.1038/ng0294-146
    • Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet. 1994;6:146-51. (Pubitemid 24188594)
    • (1994) Nature Genetics , vol.6 , Issue.2 , pp. 146-151
    • Sorensen, P.H.B.1    Lessnick, S.L.2    Lopez-Terrada, D.3    Liu, X.F.4    Triche, T.J.5    Denny, C.T.6
  • 33
    • 33745808783 scopus 로고    scopus 로고
    • Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement
    • DOI 10.1593/neo.06283
    • Yoshimoto M, Joshua AM, Chilton-Macneill S, Bayani J, Selvarajah S, Evans AJ, et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia. 2006;8:465-9. (Pubitemid 44035330)
    • (2006) Neoplasia , vol.8 , Issue.6 , pp. 465-469
    • Yoshimoto, M.1    Joshua, A.M.2    Chilton-MacNeill, S.3    Bayani, J.4    Selvarajah, S.5    Evans, A.J.6    Zielenska, M.7    Squire, J.A.8
  • 39
    • 35648948853 scopus 로고    scopus 로고
    • TMPRSS2-ERG Fusion Heterogeneity in Multifocal Prostate Cancer: Clinical and Biologic Implications
    • DOI 10.1016/j.urology.2007.08.032, PII S0090429507020146
    • Barry M, Perner S, Demichelis F, Rubin MA. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007;70:630-3. (Pubitemid 350030260)
    • (2007) Urology , vol.70 , Issue.4 , pp. 630-633
    • Barry, M.1    Perner, S.2    Demichelis, F.3    Rubin, M.A.4
  • 41
    • 48249150750 scopus 로고    scopus 로고
    • Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer
    • Attard G, Clark J, Ambroisine L, Mills IG, Fisher G, Flohr P, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer. 2008;99:314-20.
    • (2008) Br J Cancer , vol.99 , pp. 314-320
    • Attard, G.1    Clark, J.2    Ambroisine, L.3    Mills, I.G.4    Fisher, G.5    Flohr, P.6
  • 42
    • 33845329915 scopus 로고    scopus 로고
    • TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer
    • DOI 10.1158/0008-5472.CAN-06-1871
    • Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res. 2006;66:10658-63. (Pubitemid 44876959)
    • (2006) Cancer Research , vol.66 , Issue.22 , pp. 10658-10663
    • Hermans, K.G.1    Van Marion, R.2    Van Dekken, H.3    Jenster, G.4    Van Weerden, W.M.5    Trapman, J.6
  • 44
    • 79951548592 scopus 로고    scopus 로고
    • TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients
    • Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate. 2011;71:489-97.
    • (2011) Prostate , vol.71 , pp. 489-497
    • Magi-Galluzzi, C.1    Tsusuki, T.2    Elson, P.3    Simmerman, K.4    LaFargue, C.5    Esgueva, R.6
  • 45
    • 34548863661 scopus 로고    scopus 로고
    • Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer
    • DOI 10.1158/1078-0432.CCR-07-0700
    • Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res. 2007;13:5103-8. (Pubitemid 47502077)
    • (2007) Clinical Cancer Research , vol.13 , Issue.17 , pp. 5103-5108
    • Hessels, D.1    Smit, F.P.2    Verhaegh, G.W.3    Witjes, J.A.4    Cornel, E.B.5    Schalken, J.A.6
  • 46
    • 77649160775 scopus 로고    scopus 로고
    • Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer
    • Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, et al. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer. Clin Cancer Res. 2010;16:1572-6.
    • (2010) Clin Cancer Res , vol.16 , pp. 1572-1576
    • Rice, K.R.1    Chen, Y.2    Ali, A.3    Whitman, E.J.4    Blase, A.5    Ibrahim, M.6
  • 47
    • 84855983932 scopus 로고    scopus 로고
    • Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
    • Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol. 2011.
    • (2011) Urol Oncol
    • Salami, S.S.1    Schmidt, F.2    Laxman, B.3    Regan, M.M.4    Rickman, D.S.5    Scherr, D.6
  • 49
    • 51449111266 scopus 로고    scopus 로고
    • GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: Implications for tissue-based diagnostics
    • Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolls A, Lein M, et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer. 2008;99:939-48.
    • (2008) Br J Cancer , vol.99 , pp. 939-948
    • Kristiansen, G.1    Fritzsche, F.R.2    Wassermann, K.3    Jager, C.4    Tolls, A.5    Lein, M.6
  • 52
    • 0032830265 scopus 로고    scopus 로고
    • Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma
    • DOI 10.1016/S0022-5347(01)62092-5
    • Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182-7. (Pubitemid 29422316)
    • (1999) Journal of Urology , vol.161 , Issue.1 , pp. 182-187
    • Adler, H.L.1    McCurdy, M.A.2    Kattan, M.W.3    Timme, T.L.4    Scardino, P.T.5    Thompson, T.C.6
  • 53
    • 1642392553 scopus 로고    scopus 로고
    • 1 and Interleukin 6 and Its Soluble Receptor with Prostate Cancer Progression
    • DOI 10.1158/1078-0432.CCR-0768-03
    • Shariat SF, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, et al. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res. 2004;10:1992-9. (Pubitemid 38375558)
    • (2004) Clinical Cancer Research , vol.10 , Issue.6 , pp. 1992-1999
    • Shariat, S.F.1    Kattan, M.W.2    Traxel, E.3    Andrews, B.4    Zhu, K.5    Wheeler, T.M.6    Slawin, K.M.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.